EPHA2 and neoplasm: [64] found the CAR‐T cells targeting fibroblast activation protein α (FAP) in the tumor‐related matrix in combination with CAR‐T cells targeting the erythropoietin‐producing hepatocellular carcinoma A2 (EphA2) antigen could significantly increase the anti‐tumor effect and prolong the survival time of tumor‐bearing mice.